Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC) Meeting Abstract


Authors: Traina, T. A.; Kaufman, P. A.; Cadoo, K. A.; Hudis, C. A.; Chang, C.; Berrak, E.; Song, J.; Cox, D.; Seidman, A. D.
Abstract Title: Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC)
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613201988
PROVIDER: wos
Notes: Meeting Abstract: TPS670^ -- Source: Wos
MSK Authors
  1. Andrew D Seidman
    241 Seidman
  2. Clifford Hudis
    822 Hudis
  3. Tiffany A Traina
    146 Traina
  4. Karen Anne Cadoo
    25 Cadoo
  5. Cassandra Beatrice Chang
    4 Chang